ArticleJHEP reports : innovation in hepatology2026
Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsChronic HBV infection has an increasing death toll, but curative therapies are lacking. The study aimed to determine whether long-term suppression of viral antigens using RNA-interference restores HBV-specific immunity and achieves durable virus control, and how long HBV antigens must be suppressed to enable therapeutic vaccination to restore immunity.
methodsHBV-transgenic or AAV-HBV-infected, HBV-carrier mice were treated for up to 7 months with liver-directed small interfering RNAs (siRNAs) or short-hairpin RNAs (shRNAs) that target all HBV transcripts. The antiviral effect and development of B- and T-cell immunity were evaluated. A subcohort of mice received the heterologous prime/boost therapeutic vaccine, TherVacB, before cessation of siRNA.
resultsContinuous siRNA therapy reduced HBsAg by up to 4 log
conclusionsOur data show that, in addition to suppressing viral antigens, immune stimulation is necessary to achieve long-lasting HBV control after treatment discontinuation. These results will help design clinical trials that can ultimately achieve HBV control. IMPACT AND IMPLICATIONS: Drug entities in development to cure chronic hepatitis B include direct-acting antivirals, nucleic acid-based therapeutics, immunotherapies, and combinations thereof. In our study, long-term suppression of HBV in HBV-carrier mice using siRNAs targeting all HBV antigens neither allowed spontaneous reconstitution of T-cell immunity nor sustained HBV control, even when accompanied by anti-HBs seroconversion. However, prolonged viral antigen suppression by siRNA enhanced the efficacy of therapeutic vaccination. Our study highlights that achieving loss of viral parameters from serum, or even anti-HBe/HBs seroconversion, should not represent the ultimate goal of curative therapy, but rather be viewed as a prerequisite that empowers immunostimulatory drugs to induce curative T-cell responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.